Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subject to Rule 16b-3
| RCKT Stock | USD 12.56 0.16 1.26% |
Slightly above 62% of Rocket Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Rocket Pharmaceuticals stock suggests that many investors are alarmed at this time. Rocket Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Rocket Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Rocket |
Filed transaction by Rocket Pharmaceuticals Officer: See Remarks. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at gurufocus.com
 |
Rocket Pharmaceuticals Fundamental Analysis
We analyze Rocket Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Rocket Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Rocket Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rocket Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rocket Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rocket Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Rocket Pharmaceuticals Related Equities
| INZY | Inozyme Pharma | 7.72 | ||||
| SLDB | Solid Biosciences | 6.15 | ||||
| LRMR | Larimar Therapeutics | 4.24 | ||||
| MGTX | MeiraGTx Holdings | 2.39 | ||||
| VRDN | Viridian Therapeutics | 2.18 | ||||
| SNDX | Syndax Pharmaceuticals | 2.06 | ||||
| MRUS | Merus BV | 2.03 | ||||
| STOK | Stoke Therapeutics | 1.95 | ||||
| PLRX | Pliant Therapeutics | 1.88 | ||||
| PCVX | Vaxcyte | 1.87 | ||||
| MIRM | Mirum Pharmaceuticals | 1.81 | ||||
| STRO | Sutro Biopharma | 1.04 | ||||
| CYTK | Cytokinetics | 0.88 | ||||
| REPL | Replimune | 0.48 | ||||
| RVMD | Revolution Medicines | 0.27 | ||||
| QURE | Uniqure NV | 0.61 | ||||
| RYTM | Rhythm Pharmaceuticals | 0.75 | ||||
| DAWN | Day One | 0.94 | ||||
| RGNX | Regenxbio | 1.15 | ||||
| DYN | Dyne Therapeutics | 2.75 |
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.